Details

Autor(en) / Beteiligte

• Chai, Annie Wai Yeeng
• Cheung, Arthur Kwok Leung
• Dai, Wei
• Ko, Josephine Mun Yee
• Lee, Nikki Pui Yue
• Chan, Kin Tak
• Law, Simon Ying-Kit
• Lung, Maria Li

Titel

Elevated levels of serum nidogen-2 in esophageal squamous cell carcinoma

Ist Teil von

• Cancer biomarkers : section A of Disease markers, 2018-02, Vol.21 (3), p.583-590

Ort / Verlag

Netherlands

Erscheinungsjahr

2018

Quelle

MEDLINE

Beschreibungen/Notizen

• Nidogen-2 (NID2), a secretory basement membrane protein, has been implicated as a potential biomarker in ovarian cancer and hepatocellular carcinoma. In this study, we aimed to investigate the utility of detecting serum NID2 levels for identification of esophageal squamous cell carcinoma (ESCC) patients and prediction of poor survival outcome. Using an in-house NID2 enzyme-linked immunosorbent assay (ELISA), serum samples from 101 ESCC patients and 50 healthy controls were screened for their NID2 levels. The serum NID2 levels in ESCC patients (median 24.4 μg/L) are significantly higher (p= 4.3e-09) than that of the healthy controls (median 15.85 μg/L). The receiver operating characteristic (ROC) curve demonstrated an area under the curve of 0.756. At the threshold of 17.95 μg/L, the sensitivity and specificity achieved are 0.76 and 0.63, respectively. Kaplan-Meier survival analysis revealed that patients with high serum NID2 levels (⩾ 32.6 μg/L) have significantly higher risk of death (HR = 1.984, 95% CI: 1.175-3.349; log-rank p-value = 0.012) compared to those with low serum NID2 levels (< 20.0 μg/L). In conclusion, we show that detecting the elevation of serum NID2 levels has potential diagnostic and prognostic value for ESCC patients.